Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Scoping review summarizing preclinical mechanisms and mixed clinical trial literature without systematic quantitative synthesis.
PubMed 40635462 · doi:10.1177/1877718X251355112
What was done
The authors performed a scoping review synthesizing epidemiologic, preclinical (cellular and animal models), and clinical trial evidence regarding the proposed neuroprotective mechanisms and therapeutic potential of nicotine in Parkinson's disease.
What was found
The abstract reports no numerical findings. It notes that while epidemiologic data associate smoking with reduced Parkinson's disease risk and animal models show nicotine attenuates dopaminergic neuron loss via nicotinic acetylcholine receptors and anti-inflammatory pathways, clinical trials in patients with Parkinson's disease have yielded mixed results and largely failed to demonstrate benefit.
Why it matters
The review clarifies the disconnect between mechanistic bench evidence and translational clinical outcomes. Due to the lack of proven clinical efficacy, neither smoking nor nicotine is recommended for preventing or treating Parkinson's disease.
Limits
The abstract provides no study counts, search parameters, or quantitative effect sizes. Preclinical findings from chemical toxicity models may not reflect human pathophysiology, and human trials have not demonstrated consistent disease-modifying or symptomatic benefit.
Cited by
- partial Nicotine protects dopaminergic neurons and cholinergic neurons despite raising blood pressure.